m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG01055)
Name
Astemizole
Synonyms
1-(p-Fluorobenzyl)-2-((1-(p-methoxyphenethyl)-4-piperidyl)amino)benzimidazole; AlacanBrand of Astemizole; Alermizol; Alonga Brand of Astemizole; Alonga, Astemizol; Astemina; Astemisan; Astemisol; Astemison; Astemizol; Astemizol Alonga; Astemizol [German]; Astemizol [INN-Spanish]; Astemizol ratiopharm; Astemizole (JAN/USP/INN); Astemizole Alacan Brand; Astemizole Alonga Brand; Astemizole Byk Brand; Astemizole Diba Brand; Astemizole Elfar Brand; Astemizole Esteve Brand; Astemizole Fustery Brand; Astemizole ICN Brand; Astemizole Janssen Brand; Astemizole Lesvi Brand; Astemizole McNeil Brand; Astemizole Medinsa Brand; Astemizole Merck Brand; Astemizole Senosiain Brand; Astemizole Septa Brand; Astemizole Smaller Brand; Astemizole Urbion Brand; Astemizole Vita Brand; Astemizole [USAN:BAN:INN]; Astemizole ratiopharm Brand; Astemizolum; Astemizolum [INN-Latin]; Astesen; Byk Brand of Astemizole; Diba Brand of Astemizole; Elfar Brand of Astemizole; Emdar; Esmacen;Fustermizol; Esteve Brand of Astemizole; Fustery Brand of Astemizole; GNF-PF-2461; HISMANAL (TN); Hestazol; Hestazol, Kelp, Laridal, Retolen, Wareezol, HSBD 6799, BRN 4830190; Hismanal; Histamen; Histaminos; Histazol; Hubermizol; ICN Brand of Astemizole; Janssen Brand of Astemizole; Kelp; Laridal; Lesvi Brand of Astemizole; MJD-30; McNeil Brand of Astemizole; Medinsa Brand of Astemizole; Merck Brand of Astemizole; Metodih; Metodik; Nono-Nastizol A; Novo-mastizol A; Paralergin; R 42512; R 43 512; R-43-512; R-43512; R43512; Ratiopharm Brand of Astemizole; Ratiopharm, Astemizol; Reig Jofre Brand of Astemizole; Retolen; Rifedot; Rimbol; Romadin; Senosiain Brand of Astemizole; Septa Brand of Astemizole; Simprox; Smaller Brand of Astemizole; Urbion Brand of Astemizole; Urdrim; Vita Brand of Astemizole; Wareezol; Waruzol; [3H]Astemizole
    Click to Show/Hide
Status
Withdrawn
Structure
Formula
C28H31FN4O
InChI
1S/C28H31FN4O/c1-34-25-12-8-21(9-13-25)14-17-32-18-15-24(16-19-32)30-28-31-26-4-2-3-5-27(26)33(28)20-22-6-10-23(29)11-7-22/h2-13,24H,14-20H2,1H3,(H,30,31)
InChIKey
GXDALQBWZGODGZ-UHFFFAOYSA-N
PubChem CID
2247
VARIDT Drug ID
DR00705
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
P-glycoprotein 1 (ABCB1)
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary P-glycoprotein 1 (ABCB1) is a therapeutic target for Astemizole. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Astemizole through regulating the expression of P-glycoprotein 1 (ABCB1). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary P-glycoprotein 1 (ABCB1) is a therapeutic target for Astemizole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Astemizole through regulating the expression of P-glycoprotein 1 (ABCB1). [2], [3]
References
Ref 1 Binding of RNA m6A by IGF2BP3 triggers chemoresistance of HCT8 cells via upregulation of ABCB1. Am J Cancer Res. 2021 Apr 15;11(4):1428-1445. eCollection 2021.
Ref 2 Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
Ref 3 METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner. Exp Mol Med. 2021 Jan;53(1):91-102. doi: 10.1038/s12276-020-00510-w. Epub 2021 Jan 8.